Your browser doesn't support javascript.
Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China.
Li, Zhongjie; Guan, Xuhua; Mao, Naiying; Luo, Huiming; Qin, Ying; He, Na; Zhu, Zhen; Yu, Jianxing; Li, Yu; Liu, Jianhua; An, Zhijie; Gao, Wenjing; Wang, Xiaoli; Sun, Xiaodong; Song, Tie; Yang, Xingfen; Wu, Ming; Wu, Xianping; Yao, Wenqing; Peng, Zhibin; Sun, Junling; Wang, Liping; Guo, Qing; Xiang, Nijuan; Liu, Jun; Zhang, Bike; Su, Xuemei; Rodewald, Lance; Li, Liming; Xu, Wenbo; Shen, Hongbing; Feng, Zijian; Gao, George F.
  • Li Z; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Guan X; Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China.
  • Mao N; National Institute for Viral Disease Control and Prevention (China CDC), Beijing, China.
  • Luo H; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Qin Y; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • He N; Fudan University, Shanghai, China.
  • Zhu Z; National Institute for Viral Disease Control and Prevention (China CDC), Beijing, China.
  • Yu J; National Institute for Communicable Disease Control and Prevention (China CDC), Beijing, China.
  • Li Y; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Liu J; Guangzhou Municipal Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
  • An Z; National Immunization Programme (China CDC), Beijing, China.
  • Gao W; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
  • Wang X; Beijing Center for Disease Control and Prevention, Beijing, China.
  • Sun X; Shanghai Center for Disease Control and Prevention, Shanghai, China.
  • Song T; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
  • Yang X; School of Public Health, Southern Medical University, Guangzhou, Guangdong, China.
  • Wu M; Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.
  • Wu X; Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan, China.
  • Yao W; Liaoning Provincial Center for Disease Control and Prevention, Shenyang, Liaoning, China.
  • Peng Z; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Sun J; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Wang L; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Guo Q; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Xiang N; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Liu J; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Zhang B; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Su X; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Rodewald L; Beijing Center for Disease Control and Prevention, Beijing, China.
  • Li L; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Xu W; Peking University Center for Public Health and Epidemic Preparedness & Response.
  • Shen H; Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China.
  • Feng Z; National Institute for Viral Disease Control and Prevention (China CDC), Beijing, China.
  • Gao GF; Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
Lancet Reg Health West Pac ; 8: 100094, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1082570
ABSTRACT

BACKGROUND:

China implemented containment measures to stop SARS-CoV-2 transmission in response to the COVID-19 epidemic. After the first epidemic wave, we conducted population-based serological surveys to determine extent of infection, risk factors for infection, and neutralization antibody levels to assess the real infections in the random sampled population.

METHODS:

We used a multistage, stratified cluster random sampling strategy to conduct serological surveys in three areas - Wuhan, Hubei Province outside Wuhan, and six provinces selected on COVID-19 incidence and containment strategy. Participants were consenting individuals >1 year old who resided in the survey area >14 days during the epidemic. Provinces screened sera for SARS-CoV-2-specific IgM, IgG, and total antibody by two lateral flow immunoassays and one magnetic chemiluminescence enzyme immunoassay; positive samples were verified by micro-neutralization assay.

FINDINGS:

We enrolled 34,857 participants (overall response rate, 92%); 427 were positive by micro-neutralization assay. Wuhan had the highest weighted seroprevalence (4•43%, 95% confidence interval [95%CI]=3•48%-5•62%), followed by Hubei-ex-Wuhan (0•44%, 95%CI=0•26%-0•76%), and the other provinces (<0•1%). Living in Wuhan (adjusted odds ratio aOR=13•70, 95%CI= 7•91-23•75), contact with COVID-19 patients (aOR=7•35, 95%CI=5•05-10•69), and age over 40 (aOR=1•36, 95%CI=1•07-1•72) were significantly associated with SARS-CoV-2 infection. Among seropositives, 101 (24%) reported symptoms and had higher geometric mean neutralizing antibody titers than among the 326 (76%) without symptoms (30±2•4 vs 15±2•1, p<0•001).

INTERPRETATION:

The low overall extent of infection and steep gradient of seropositivity from Wuhan to the outer provinces provide evidence supporting the success of containment of the first wave of COVID-19 in China. SARS-CoV-2 infection was largely asymptomatic, emphasizing the importance of active case finding and physical distancing. Virtually the entire population of China remains susceptible to SARS-CoV-2; vaccination will be needed for long-term protection.

FUNDING:

This study was supported by the Ministry of Science and Technology (2020YFC0846900) and the National Natural Science Foundation of China (82041026, 82041027, 82041028, 82041029, 82041030, 82041032, 82041033).

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Language: English Journal: Lancet Reg Health West Pac Year: 2021 Document Type: Article Affiliation country: J.lanwpc.2021.100094

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Language: English Journal: Lancet Reg Health West Pac Year: 2021 Document Type: Article Affiliation country: J.lanwpc.2021.100094